Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00046176
Status:
COMPLETED
Last Update Posted:
2020-03-24
First Post:
2002-09-20
Brief Title:
A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients
Sponsor:
ViiV Healthcare
Organization:
ViiV Healthcare
Study Overview
Official Title:
A Phase III 48-Week Open-Label Randomized Multicenter Study of the Safety and Efficacy of the AbacavirLamivudine Fixed-Dose Combination Tablet Administered QD Versus Abacavir Lamivudine Administered BID in Combination With a PI or NNRTI in Antiretroviral Experienced Patients
Status:
COMPLETED
Status Verified Date:
2020-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a 48-week study designed to evaluate the safety and efficacy of a fixed-dose combination tablet administered once-a-day versus the individual tablets administered twice-a-day within 3-drug combination regimens in ART antiretroviral-experienced HIV-1 infected patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None